Needle-Free Connectors

BD offers a range of five needle-free connectors designed to help reduce the risk of IV infectious complications such as central line bloodstream infection (CLABSI).

Our portfolio of the needle-free connectors demonstrates effectiveness and safety with patented innovations and design features aligned with the recommendations of the Centers for Disease Control and Prevention (CDC)¹ and the International Nosocomial Infection Control Consortium (INICC).²

BD MaxZero needle-free connector

The BD MaxZero connector has shown solid results in preventing the risk of infection.⁴

BD Q-Syte needle-free connector

The BD Q-Syte luer access split septum features a simple internal design with a straight, open fluid path for high flow rate cllinical practice needs.

BD MaxPlus needle-free connector

The BD MaxPlus connector is the only needle-free connector with an FDA-cleared label statement demonstrating a reduction in CLABSI.³

BD NeutraClear needle-free connector

A compact, transparent needle-free connector with neutral displacement. The BD NeutraClear connector has a reverse split septum design with an internal blunt cannula.

BD SmartSite needle-free connector

A widely used technology offering a leak-free system for chemotherapy when used in combination with Texium devices, whilst also enabling connector standardisation with the BD SmartSite port on the BD infusion pumps.

References

O'Grady NP, Alexander M, Burns LA et al. Guidelines for the prevention of intravascular catheter-related infections. CDC. 2011; Section 54.
International Nosocomial Infection Control Consortium (INICC) Care Bundles to Prevent Central and Peripheral Line-Related Bloodstream Infections. http://www.inicc.org/media/docs/2017-INICCBSIPreventionGuidelines.pdf. Published January 1, 2017. Accessed July 14, 2021.
Data on File: REF-3786 - PS100009 and PS100010 / 510(k) Number: K051939 and K072542 (6 Aug 2014).
Tabak YP, Johannes RS, Sun X, Crosby CT, Jarvis WR. Innovative use of existing public and private data sources for postmarket surveillance of central line-associated bloodstream infections associated with intravenous needleless connectors. J Infus Nurs. 2016;39(5):328-335.

BD-35577 (08/2021)